德琪医药－Ｂ招股说明书

– 5 –

1 (s)N D A FDA NDA 2020 2021 2

3 4 Origincell ATG-101 5

6 7 RAS RAF AML *

**

=

(i) (ii) NDA (iii) ATG-010 (selinexor) B NSCLC ATG-008 (onatasertib) HCC NSCLC 2019 B HCC NSCLC 68,200 137,600 369,400 761,000

1

***

ATG-010 (selinexor)

1 2.4 2

III BOSTON *IIb STORM *Ib/II STOMP **IIb SADAL ****

**

*** B

2018 5 23 II MARCH (NCT03944057)

2020 2021 NDA IND 2020 10 ATG-010 (selinexor) III 2021

II SEARCH (NCT03992339) 2021 NDA DLBCL 2020 Karyopharm ATG-010 (selinexor) R-GDP DLBCL